Blephamide
Pricing Report NDC 0023-0313-04

View Wholesale Price per Unit, Acquisition Costs, and Historic Pricing Trends
Table of Contents
  1. Current Pricing Information
  2. Pricing History

Current Package Pricing Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

The latest wholesale acquisition cost for Blephamide (NDC 0023-0313-04) is $40.01771 per GM. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Jan 01, 2019.

As a provided by Allergan, Inc., this medication is distributed in a 1 TUBE in 1 CARTON / 3.5 g in 1 TUBE configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.

NADAC Pricing Summary

NADAC pricing snapshot for this package NDC

Acquisition Cost
$40.01771
Per GM

Pricing Unit
Per GM Pricing Unit
Indicates the billing unit (ML, GM or EA).
Effective Date
Jan 01, 2019
Billable Units
3.5 GM
Estimated Package Price
$140.06
Data Status
As of Jan 15, 2020
Pharmacy Source Pharmacy Type Indicator
Data collected from Chain/Independent pharmacy surveys.
C/I - Chain or Independent Pharmacy
Rate Classification Classification for Rate Setting
Indicates if the NDC is Brand (B) or Generic (G).
B-ANDA - Abbreviated New Drug Application
Package NDC
0023-0313-04
Description
1 TUBE in 1 CARTON / 3.5 g in 1 TUBE
Pricing Methodology Explanation
The NADAC was carried forward from the previous file.
The NADAC was calculated based on package size.
The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.

Historical Pricing Trends & Acquisition Cost Benchmarks

Since May 2013, the NADAC wholesale price for (NDC ) has moved within a range of $23.06996 to $40.01771 per GM. Over this 5 years and 7 months period, the pricing trend reflects the shifting acquisition costs reported by retail and chain pharmacies to the Centers for Medicare and Medicaid Services (CMS). The following interactive chart and historical table detail every recorded price adjustment based on these federal surveys.

Price Range
$23.0700 - $40.0177
Market Volatility
73.46% Variance
Latest Trend
4.90%
Date Unit Price Unit Source Method Rate
Jan 01, 2019 $40.01771 GMC/I - Chain or Independent PharmacyCode 3, 5, 6B-ANDA - Abbreviated New Drug Application
Jan 01, 2019 $40.01771 GMC/I - Chain or Independent PharmacyCode 4, 5, 6B-ANDA - Abbreviated New Drug Application
Jan 01, 2018 $38.14734 GMC/I - Chain or Independent PharmacyCode 3, 5, 6B-ANDA - Abbreviated New Drug Application
Jan 01, 2018 $38.14734 GMC/I - Chain or Independent PharmacyCode 4, 5, 6B-ANDA - Abbreviated New Drug Application
Jan 01, 2017 $34.83839 GMC/I - Chain or Independent PharmacyCode 3, 5, 6B-ANDA - Abbreviated New Drug Application
Jan 01, 2017 $34.83839 GMC/I - Chain or Independent PharmacyCode 4, 5, 6B-ANDA - Abbreviated New Drug Application
Jan 01, 2016 $31.81559 GMC/I - Chain or Independent PharmacyCode 2, 5, 6B-ANDA - Abbreviated New Drug Application
Jan 01, 2016 $31.81559 GMC/I - Chain or Independent PharmacyCode 3, 5, 6B-ANDA - Abbreviated New Drug Application
Jan 01, 2016 $31.81559 GMC/I - Chain or Independent PharmacyCode 4, 5, 6B-ANDA - Abbreviated New Drug Application
Jun 17, 2015 $28.94958 GMC/I - Chain or Independent PharmacyCode 3, 5, 6B-ANDA - Abbreviated New Drug Application
Jun 17, 2015 $28.94958 GMC/I - Chain or Independent PharmacyCode 4, 5, 6B-ANDA - Abbreviated New Drug Application
May 30, 2015 $29.67462 GMC/I - Chain or Independent PharmacyCode 3, 5, 6B-ANDA - Abbreviated New Drug Application
Apr 22, 2015 $27.10036 GMC/I - Chain or Independent PharmacyCode 1, 5, 6B-ANDA - Abbreviated New Drug Application
Apr 22, 2015 $27.10036 GMC/I - Chain or Independent PharmacyCode 2, 5, 6B-ANDA - Abbreviated New Drug Application
Jan 01, 2015 $26.55350 GMC/I - Chain or Independent PharmacyCode 2, 5, 6B-ANDA - Abbreviated New Drug Application
Jan 01, 2015 $26.55350 GMC/I - Chain or Independent PharmacyCode 3, 5, 6B-ANDA - Abbreviated New Drug Application
Sep 17, 2014 $24.58657 GMC/I - Chain or Independent PharmacyCode 1, 5, 6B-ANDA - Abbreviated New Drug Application
Sep 17, 2014 $24.58657 GMC/I - Chain or Independent PharmacyCode 2, 5, 6B-ANDA - Abbreviated New Drug Application
Sep 17, 2014 $24.58657 GMC/I - Chain or Independent PharmacyCode 4, 5, 6B-ANDA - Abbreviated New Drug Application
Nov 23, 2013 $24.56304 GMC/I - Chain or Independent PharmacyCode 2, 5B-ANDA - Abbreviated New Drug Application
Nov 23, 2013 $24.56304 GMC/I - Chain or Independent PharmacyCode 2, 5, 6B-ANDA - Abbreviated New Drug Application
Nov 23, 2013 $24.56304 GMC/I - Chain or Independent PharmacyCode 3, 5B-ANDA - Abbreviated New Drug Application
Nov 23, 2013 $24.56304 GMC/I - Chain or Independent PharmacyCode 4, 5B-ANDA - Abbreviated New Drug Application
May 24, 2013 $23.06996 GMC/I - Chain or Independent PharmacyCode 4, 5B-ANDA - Abbreviated New Drug Application

Pricing Methodology Legend

  • Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey.
  • Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file.
  • Code 3: The NADAC based on survey data has been adjusted to reflect changes in published pricing, or as a result of an inquiry to the help desk.
  • Code 4: The NADAC was carried forward from the previous file.
  • Code 5: The NADAC was calculated based on package size.
  • Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.

Understanding NADAC Pricing Data

The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.

Important Price Distinction:

The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.

NADAC Pricing Data Last Updated on: July 08, 2026